版本:
中国

BRIEF-Ignyta updates progress towards NDA submissions

April 27 Ignyta Inc:

* Ignyta updates progress towards entrectinib dual trk and ros1 NDA submissions

* Ignyta - tracking towards dual NDA submissions in TRK and ros1 in 2018 if supported by clinical data, anticipated us commercial launch in both indications in 2019 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐